Insulet and Dexcom Partner to Offer Choices for Animas Users
October 18 2017 - 4:04PM
Business Wire
Insulet’s Welcome Program for Animas®
Users Now Includes Optional Dexcom G5® Mobile CGM Upgrade
Insulet Corporation (NASDAQ: PODD) (Insulet or the
Company) the leader in tubeless insulin pump technology
with its Omnipod® Insulin Management System (Omnipod System),
is partnering with DexCom, Inc. (Dexcom) to provide
the Omnipod System and a $200 gift card from Dexcom which can
be used towards the purchase of a Dexcom G5® Mobile CGM (Continuous
Glucose Monitoring) for qualified Animas® insulin pump users.1 The
program provides Animas users with an easy way to experience
freedom from tubing and the ability to dose insulin without finger
pricks.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171018006532/en/
The Omnipod Welcome Program includes a no cost trial of the
Omnipod System, a free box of Pods (10 count), and the opportunity
to receive a $200 gift card for completing a Dexcom patient survey
to upgrade to the Dexcom G5 CGM.2 Animas pump switchers who have
recently taken advantage of the existing Omnipod Welcome Program
may still take advantage of this Dexcom offer as long as they are
not an already-existing customer of Dexcom.
“We created this program to provide a way for Animas users to
experience the freedom of the Omnipod System with the peace of mind
of Dexcom’s market-leading CGM,” said Bret Christensen, Chief
Commercial Officer of Insulet. “Managing diabetes is a very
personal decision and we strongly support an individual’s right to
choice when it comes to their diabetes management. This partnership
is just one example of our commitment to support people with
diabetes today and over the long term.”
"Dexcom is excited to partner with Insulet to offer this special
promotion,” said Rick Doubleday, Chief Commercial Officer of
Dexcom. "This provides Animas users the opportunity to upgrade to
our best-selling Dexcom G5 Mobile CGM and have easier access to the
only tubeless pump system in the U.S.”
As the number one pediatric preferred pump3, which is also
quickly gaining adoption with adults, the Omnipod System uses a
tubeless, waterproof patch-pump technology that offers users
significant quality of life benefits. The differentiated design
provides up to 72 hours of nonstop, discreet insulin delivery, and
more choice for site selection. It eliminates the burden associated
with multiple daily injections and the complexity associated with
traditional tubed pumps. When used with the Dexcom G5 Mobile CGM,
users will benefit from fewer finger sticks, fewer components to
carry and wear, and access to pump and blood glucose data from
their smart-phone with Insulet provided Glooko.
For full offer details and to get started, Animas patients
should call the Insulet Customer Care Team at 1-888-643-8763. Offer
terms and conditions are subject to change. Please click
here for full promotion details.
1The Omnipod Insulin Management System and the Dexcom G5 CGM are
not integrated, are sold separately, and function
independently.
2These promotions are two independent offerings and therefore an
individual may take advantage of either one separately or both. You
may be required to submit a form directly to Dexcom.
3dQ&A Q3 2016 Patient Panel Survey. Share of parents of
children with type 1 diabetes on an insulin pump who had chosen the
Omnipod® was higher than for other pumps. Statistical significance
of results calculated at the 95% confidence level.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD) is an innovative medical
device company dedicated to making the lives of people with
diabetes easier. Insulet seeks to expand the use of
insulin pump therapy with its Omnipod Insulin Management System
among people with insulin-dependent diabetes. The Omnipod System is
a revolutionary and easy-to-use tubeless insulin pump that provides
up to three days of non-stop insulin delivery, without the need to
see or handle a needle. Insulet's Delivery Systems
business partners with global pharmaceutical and biotechnology
companies to adapt the Omnipod technology platform for the delivery
of subcutaneous drugs across multiple therapeutic areas. Founded in
2000, Insulet Corporation is based
in Billerica, Massachusetts. For more information, please
visit: http://www.myomnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements
concerning Insulet's expectations, anticipations,
intentions, beliefs or strategies regarding the future. These
forward-looking statements are based on its current expectations
and beliefs concerning future developments and their potential
effects on Insulet. There can be no assurance that future
developments affecting Insulet will be those that it has
anticipated. These forward-looking statements involve a number of
risks, uncertainties (some of which are beyond its control) or
other assumptions that may cause actual results or performance to
be materially different from those expressed or implied by these
forward-looking statements, and other risks and uncertainties
described in its Annual Report on Form 10-K, which was filed with
the Securities and Exchange Commission on February
28, 2017 in the section entitled "Risk Factors," and in its
other filings from time to time with the Securities and
Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should any of its assumptions prove
incorrect, actual results may vary in material respects from those
projected in these forward-looking
statements. Insulet undertakes no obligation to publicly
update or revise any forward-looking statements.
© 2017 Insulet Corporation and Omnipod are trademarks
or registered trademarks of Insulet Corporation. All rights
reserved. All other trademarks are the property of their respective
owners. The use of third party trademarks does not constitute an
endorsement or imply a relationship or other affiliation.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171018006532/en/
Investor Relations and Media Contact:Insulet
CorporationDeborah R. Gordon, 978-600-7717Vice President, Investor
Relations and Corporate Communicationsdgordon@insulet.com
Insulet (NASDAQ:PODD)
Historical Stock Chart
From Apr 2024 to May 2024
Insulet (NASDAQ:PODD)
Historical Stock Chart
From May 2023 to May 2024